Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Dan Liu(Machine Intelligence Research Institute), Lin Shen(Hangzhou Normal University), Jian Huang(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongsheng Wang(Capital Medical University), Ying Cheng(Jilin Province Tumor Hospital), Xiaojun Xiang(Ministry of Agriculture and Rural Affairs), Yunpeng Liu(Capital Medical University), Pan Liu(China University of Geosciences (Beijing)), Xiaojing Zhang(Southwest University), Weiqing Han(Central South University), Mingjun Li(First Affiliated Hospital of Zhengzhou University), Zhigang Huang(Sichuan University), Suxia Luo(Zhengzhou University), Tianshu Liu(Sun Yat-sen University), Linna Wang(Jiangsu Hengrui Medicine (China)), Dong Yan(Nanjing University of Chinese Medicine), Xinshuai Wang(University of Chinese Academy of Sciences), Xianli Yin(Central South University), Haiping Jiang, Xianglin Yuan(Tongji University), Minghua Ge(Zhejiang Provincial People's Hospital), Yanqiao Zhang(Harbin Medical University), Jun Zhou(Peking University)
Cited by 84
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
|Molecular Cancer|2019|1.2k